Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18960248 | INSECT NEUROPEPTIDES 9 | November 2024 | November 2025 | Allow | 11 | 2 | 1 | Yes | No |
| 18812797 | GLP-1/GIP DUAL AGONISTS | August 2024 | August 2025 | Allow | 11 | 2 | 1 | No | No |
| 18650574 | ANTI-AGING STURGEON ROE TETRAPEPTIDE AND PREPARATION METHOD AND APPLICATION THEREOF | April 2024 | April 2025 | Allow | 11 | 1 | 1 | Yes | No |
| 18640676 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | April 2024 | October 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18604451 | DRUG FOR PREVENTING AND/OR TREATING POLYCYSTIC KIDNEY DISEASE | March 2024 | December 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18602026 | AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERS | March 2024 | October 2025 | Allow | 19 | 2 | 1 | No | No |
| 18598577 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | March 2024 | October 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18596026 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS | March 2024 | December 2025 | Abandon | 22 | 2 | 1 | No | No |
| 18591918 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF | February 2024 | May 2025 | Allow | 15 | 0 | 1 | Yes | No |
| 18435934 | NOVEL HYBRID ACTRIIB LIGAND TRAP PROTEINS FOR TREATING MUSCLE WASTING DISEASES | February 2024 | October 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18413417 | AQUEOUS PEPTIDE PROGRAMMING OF THE VINYLIDENE FLUORIDE FERROELECTRIC PHASE | January 2024 | January 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18413390 | TOPICAL COMPOSITIONS CONTAINING N-ACYL DIPEPTIDE DERIVATIVES AND GLYCOLIC ACID | January 2024 | October 2025 | Abandon | 21 | 2 | 1 | No | No |
| 18543288 | CROSSLINKED HYALURONIC ACID-COLLAGEN GELS FOR IMPROVING TISSUE GRAFT VIABILITY AND SOFT TISSUE AUGMENTATION | December 2023 | October 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18568888 | SURFACE LAYER PROTEIN A (SLPA) AS A THERAPEUTIC AGENT FOR THE TREATMENT OF INFLAMMATORY DISEASES | December 2023 | May 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18527616 | HYALURONIC ACID-COLLAGEN MATRICES FOR DERMAL FILLING AND VOLUMIZING APPLICATIONS | December 2023 | October 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18385946 | CNP COMPOUNDS | November 2023 | May 2024 | Allow | 6 | 0 | 1 | Yes | No |
| 18492076 | INSECT NEUROPEPTIDES 9 | October 2023 | October 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18491957 | INSECT NEUROPEPTIDES 1 | October 2023 | February 2025 | Allow | 16 | 2 | 1 | Yes | No |
| 18473627 | BROWN FAT-SELECTIVE ADIPOKINES | September 2023 | April 2025 | Allow | 18 | 2 | 1 | Yes | No |
| 18460215 | MODIFIED PEPTIDE FRAGMENTS OF CAV-1 PROTEIN AND THE USE THEREOF IN THE TREATMENT OF FIBROSIS | September 2023 | August 2025 | Allow | 23 | 0 | 1 | Yes | No |
| 18457482 | GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS AND USES THEREOF | August 2023 | May 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18450524 | RAGE PROTEINS FOR THE TREATMENT OF FIBROSIS AND DNA DAMAGE MEDIATED DISEASES | August 2023 | June 2025 | Abandon | 22 | 1 | 1 | Yes | No |
| 18227782 | COMPOUND WITH ANALGESIC EFFECT FOR USE IN PREVENTION AND TREATMENT OF PAIN | July 2023 | July 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18360773 | COMPOSITION FOR IMPROVING MILD COGNITIVE IMPAIRMENT AND METHOD FOR IMPROVING MILD COGNITIVE IMPAIRMENT | July 2023 | November 2024 | Abandon | 16 | 1 | 0 | No | No |
| 18348878 | PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEIN | July 2023 | September 2024 | Abandon | 14 | 1 | 0 | Yes | No |
| 18330109 | GROWTH PROMOTING PEPTIDES, AND USES THEREOF | June 2023 | August 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18203184 | ERYTHROPOIETIN AND ANALOGS FOR VETERINARY USE | May 2023 | August 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18318343 | COMPOSITIONS COMPRISING PCSK9-BINDING MOLECULES AND METHODS OF USE | May 2023 | May 2025 | Allow | 24 | 1 | 1 | Yes | No |
| 18144630 | Compositions Containing a Pharmacophore with Selectivity to Diseased Tissue and Methods of Making Same | May 2023 | July 2025 | Abandon | 26 | 2 | 1 | Yes | No |
| 18301761 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS | April 2023 | January 2024 | Allow | 9 | 0 | 1 | Yes | No |
| 18180002 | METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS | March 2023 | September 2024 | Abandon | 19 | 1 | 1 | No | No |
| 18118113 | Skin Compositions and Uses | March 2023 | June 2025 | Abandon | 27 | 2 | 1 | No | No |
| 18174751 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | February 2023 | November 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 18112554 | METHOD FOR ALLEVIATING DEPRESSION USING TNFAIP3-INTERACTING PROTEIN (TNIP) 1 | February 2023 | September 2025 | Abandon | 31 | 3 | 1 | No | No |
| 18169097 | ANTI-ANGIOGENIC AGENT AND METHODS OF USING SUCH AGENT | February 2023 | July 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 18160787 | ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF | January 2023 | November 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 18157307 | METHODS FOR PREVENTING AND TREATING INTRA-ABDOMINAL CANDIDIASIS | January 2023 | January 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18157293 | CYSTEINE PROTEASE INHIBITORS AND METHODS OF USE THEREOF | January 2023 | May 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18002625 | VASOPRESSIN-2 RECEPTOR ANTAGONIST PEPTIDES AND USES THEREOF | December 2022 | December 2025 | Allow | 36 | 0 | 1 | Yes | No |
| 18061699 | HISTATIN FOR CORNEAL WOUND HEALING AND OCULAR SURFACE DISEASE | December 2022 | December 2024 | Abandon | 24 | 1 | 1 | Yes | No |
| 17927623 | COMPOSITION FOR NEUTRALIZING CORONAVIRUS | November 2022 | March 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18054587 | BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN | November 2022 | September 2024 | Abandon | 22 | 0 | 1 | Yes | No |
| 18053965 | PEPTIDE FOR TREATING SEPSIS DERIVED FROM RV3364C PROTEIN OF MYCOBACTERIUM TUBERCULOSIS | November 2022 | April 2024 | Allow | 17 | 3 | 1 | Yes | No |
| 17981595 | SELF-ASSEMBLING ANTIVIRAL PRODRUGS | November 2022 | January 2024 | Allow | 15 | 1 | 1 | Yes | No |
| 18050659 | DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOF | October 2022 | March 2025 | Allow | 29 | 0 | 1 | Yes | No |
| 18050604 | DUAL AMYLIN AND CALCITONIN RECEPTOR AGONISTS AND USES THEREOF | October 2022 | March 2025 | Allow | 28 | 0 | 1 | Yes | No |
| 17921508 | FUSION POLYPEPTIDES FOR TARGET PEPTIDE PRODUCTION | October 2022 | July 2025 | Allow | 32 | 0 | 1 | Yes | No |
| 17919940 | PROTEOLYTICALLY STABLE U1-AGATOXIN-TA1B VARIANT POLYPEPTIDES FOR PEST CONTROL | October 2022 | February 2026 | Allow | 39 | 1 | 1 | Yes | No |
| 17937203 | CAS9 VARIANTS AND USES THEREOF | September 2022 | November 2025 | Allow | 38 | 1 | 1 | Yes | No |
| 17908853 | ANTIBACTERIAL PROTEIN HAVING LYTIC ACTIVITY TO BACILLUS GENUS AND METHOD FOR PREPARING THE SAME | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17823128 | HUMAN SERUM ALBUMIN VARIANTS AND USES THEREOF | August 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17898470 | NANO SMALL PEPTIDE AND ITS USE IN PREPARATION OF DRUGS FOR TREATING AND PREVENTING FUNDUS VASCULAR DISEASES | August 2022 | July 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17904142 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS FOR TREATING TP53-MUTATED ACUTE MYELOID LEUKEMIA | August 2022 | March 2026 | Abandon | 43 | 0 | 1 | No | No |
| 17818118 | PHARMACEUTICAL COMPOSITIONS FOR INHIBITING INFLAMMATORY CYTOKINES | August 2022 | March 2026 | Abandon | 43 | 5 | 1 | Yes | No |
| 17759613 | POLYPEPTIDES HAVING IMPROVED PROPERTIES | July 2022 | February 2026 | Allow | 42 | 0 | 1 | Yes | No |
| 17864486 | USES OF BREMELANOTIDE IN THERAPY FOR FEMALE SEXUAL DYSFUNCTION | July 2022 | August 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17851339 | STABILIZED PEPTIDE COMPOSITION | June 2022 | September 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17784589 | DEBARYOMYCES SPECIES AS AN INDICATOR OF NON-HEALING ULCERS IN CROHN'S DISEASE | June 2022 | November 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17783822 | Improved Cell-Permeable Nuclear Import Inhibitor Synthetic Peptide for Inhibition of Cytokine Storm or Inflammatory Disease and Use Thereof | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17757104 | PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDE THAT INHIBITS INTERACTION OF P53 AND FOXO4 | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17782610 | OPTIMIZED ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | June 2022 | July 2025 | Allow | 38 | 0 | 1 | Yes | No |
| 17756721 | ECHINOCANDIN ANALOGUES AND PREPARATION METHOD THEREFOR | June 2022 | April 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17747788 | COMPOSITIONS AND METHODS OF USING ISLET NEOGENESIS PEPTIDES AND ANALOGS THEREOF | May 2022 | June 2024 | Abandon | 25 | 2 | 1 | No | No |
| 17741692 | POLYPEPTIDE, PHOTORESIST COMPOSITION INCLUDING THE SAME, AND METHOD OF FORMING PATTERN USING THE SAME | May 2022 | October 2024 | Allow | 29 | 3 | 1 | Yes | No |
| 17740202 | PHARMACEUTICAL COMBINATION FOR USE IN GLYCEMIC CONTROL IN DIABETES TYPE 2 PATIENTS | May 2022 | November 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17737471 | CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS | May 2022 | September 2025 | Abandon | 40 | 3 | 1 | Yes | Yes |
| 17734775 | BROAD SPECTRUM INHIBITORS OF CRISPR-CAS9 | May 2022 | November 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17727579 | PTD-SMAD7 THERAPEUTICS | April 2022 | October 2023 | Abandon | 18 | 0 | 1 | No | No |
| 17709731 | ANTI-RNA VIRAL PHARMACEUTICAL COMBINATION THERAPY WITH APROTININ + anti-RNA DRUG | March 2022 | October 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17765342 | Muscle Tissue-Regenerating Agent | March 2022 | April 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17639929 | Use of Cobra neurotoxin polypeptide molecule in the treatment of nephropathy proteinuria | March 2022 | July 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17640367 | NOVEL MICROPEPTIDE HMMW AND APPLICATION THEREOF | March 2022 | October 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17653643 | METHOD FOR CONTROLLING PROTEIN DIMERIZATION USING AN INTRAMOLECULAR TO INTERMOLECULAR CONFORMATIONAL SWITCH | March 2022 | February 2026 | Allow | 47 | 1 | 1 | Yes | No |
| 17682277 | Novel Hybrid ActRIIB Ligand Trap Proteins for Treating Muscle Wasting Diseases | February 2022 | November 2023 | Allow | 20 | 1 | 1 | Yes | No |
| 17665179 | HIGHLY POTENT ACID ALPHA-GLUCOSIDASE WITH ENHANCED CARBOHYDRATES | February 2022 | October 2022 | Allow | 9 | 1 | 1 | Yes | No |
| 17586774 | PEPTIDE FOR COMPLEXING ZINC ION, COMPLEX THEREOF AND USE THEREFOR | January 2022 | February 2025 | Allow | 36 | 1 | 1 | Yes | No |
| 17629999 | COMPOSITIONS AND METHODS FOR PREPARING FACTOR XA AND DERIVATIVES | January 2022 | April 2025 | Allow | 39 | 0 | 1 | Yes | No |
| 17579455 | THERAPEUTICS DIRECTED AGAINST CORONAVIRUS | January 2022 | August 2023 | Abandon | 19 | 2 | 1 | Yes | No |
| 17627359 | ACETYLCHOLINE MODULATION OF IMMUNE FUNCTION | January 2022 | December 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17574865 | ANTI-INFLAMMATORY PEPTIDES, AND USES THEREOF | January 2022 | May 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17624672 | Modified BCL9 Mimetic Peptides | January 2022 | October 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17566368 | METHOD FOR DECREASING IMMUNOGENICITY OF PROTEIN AND PEPTIDE | December 2021 | December 2023 | Abandon | 24 | 1 | 1 | Yes | No |
| 17621807 | PEPTIDE ACETALS FOR STABILISING ENZYMES | December 2021 | March 2025 | Allow | 39 | 1 | 1 | Yes | No |
| 17619334 | METHODS FOR PROTEIN PURIFICATION | December 2021 | November 2025 | Abandon | 47 | 1 | 1 | Yes | No |
| 17618117 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | December 2021 | June 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17546739 | PREPARING METHOD OF HIGHLY FUNCTIONAL PEPTIDE DERIVED FROM KERATINOCYTE PROTEIN | December 2021 | December 2023 | Abandon | 24 | 2 | 1 | No | No |
| 17541145 | Compositions and Formulations and Methods of Production and Use Thereof | December 2021 | June 2024 | Abandon | 30 | 2 | 1 | Yes | No |
| 17538924 | OCULAR DELIVERY OF CELL PERMEANT THERAPEUTICS FOR THE TREATMENT OF RETINAL EDEMA | November 2021 | November 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17536296 | AGENTS AND METHODS FOR TREATING CBP-DEPENDENT CANCERS | November 2021 | December 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17535451 | TUMOR-SPECIFIC CLEAVABLE LINKERS | November 2021 | January 2025 | Allow | 38 | 1 | 2 | Yes | No |
| 17532978 | RECOMBINANT COLLAGEN AND ELASTIN MOLECULES AND USES THEREOF | November 2021 | August 2024 | Abandon | 33 | 2 | 1 | No | No |
| 17532597 | METHODS AND COMPOSITIONS COMPRISING A C-TERMINAL BAX PEPTIDE | November 2021 | March 2025 | Abandon | 39 | 3 | 1 | Yes | No |
| 17454931 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | November 2021 | November 2023 | Allow | 24 | 2 | 1 | Yes | No |
| 17609818 | PROTEIN INHIBITORS OF CLOSTRIDIUM DIFFICILE TOXIN B | November 2021 | August 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17512550 | Antithrombin-III Treatment of Traumatic Brain Injury | October 2021 | September 2023 | Abandon | 22 | 0 | 1 | No | No |
| 17450613 | THERAPEUTIC METHOD OF TREATMENT FOR INHIBITING TUMOR DEVELOPMENT USING TAMM-HORSFALL GLYCOPROTEIN (THP) AS IMMUNOSTIMULATING DRUG AND COMPOSITIONS | October 2021 | March 2023 | Allow | 18 | 0 | 1 | No | No |
| 17493598 | RECOMBINANT ELASTIN AND PRODUCTION THEREOF | October 2021 | November 2024 | Allow | 38 | 3 | 1 | Yes | No |
| 17600468 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | September 2021 | April 2025 | Allow | 42 | 1 | 1 | Yes | No |
| 17490156 | WOUND HEALING THERAPEUTIC HYDROGELS | September 2021 | July 2025 | Abandon | 46 | 3 | 1 | Yes | No |
| 17599625 | Reagents and Assays using Modified Integrin Domains | September 2021 | December 2024 | Allow | 39 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner KOMATSU, LI N.
With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner KOMATSU, LI N works in Art Unit 1658 and has examined 378 patent applications in our dataset. With an allowance rate of 51.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner KOMATSU, LI N's allowance rate of 51.3% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by KOMATSU, LI N receive 1.95 office actions before reaching final disposition. This places the examiner in the 48% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by KOMATSU, LI N is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +68.8% benefit to allowance rate for applications examined by KOMATSU, LI N. This interview benefit is in the 98% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 15.0% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.7% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 53.3% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 63.9% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.3% of allowed cases (in the 55% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.